Acetylsalicylic acid (ASA) and other non-steroidal anti-inflammatory drugs have been shown to potentially inhibit bone healing and bone formation in both animal and clinical studies. Due to the extensive diffusion of ASA-based long-term therapies, the implications of such a side-effect are of interest in all types of bone surgery, including bone grafting procedures and dental implant placement. In this study, we investigate the effect of ASA at therapeutic concentrations on the proliferation and osteogenic differentiation of human bone marrow stromal cells (BMSCs). Primary cultures of BMSCs were isolated and expanded. Their proliferation in response to ASA 50, 100 and 200 Jlg/ml was evaluated by MTT assay and 3H-thymidine incorporation. Cell cycle machinery was also investigated by FACS and analysis of inhibitors of cyclin-dependent kinases (CDKIs). ASA inhibited BMSC proliferation and DNA synthesis in a dose-dependent manner down to 60% of control (ASA 200 ug/ml) at 72 h. Cell cycle analysis showed a decrease ofBMSCs in the Sand G2/M phases with a concomitant accumulation in GO/ 1 in ASA treated cells. The finding was associated to increased levels of some CDKIs, namely p27 Kipl and p21 Cipl, whereas ASA did not affected p16Ink4A level at any ofthe concentrations employed. The matrix mineralization, that represents the major feature of the osteogenic commitment, was assessed by a specific staining procedure (von Kossa) and by calcium content determlnation.Both the methods demonstrated an extensive reduction (>90%) of extracellular calcification at 200 Jlg/ml ASA. On the basis of our results, we can hypothesize that the widely reported inhibition of bone healing by ASA might be sustained both by a direct anti-proliferative effect on BMSCs and by an alteration ofthe extracellular calcification.
are able to induce several adverse effects including gastrointestinal toxicity, allergic reactions and impairment of bone healing process (1, (3) (4) . An indirect confirmation of the inhibitory effect of these drugs on bone formation is provided by several clinical studies in which NSAIDs appear to be effective in preventing heterotopic ossification, a frequent complication of hip joint replacement (5) .
As it concerns ASA, Trancik et al (6) showed that this drug was able to inhibit bone ingrowth into harvest chambers implanted in rabbits, with a dose-dependent response, suggesting potential implications for the osseointegration of some medical devices, including orthopaedic prostheses and dental implants.
The inhibitory effect of ASA on bone healing was also observed when commercially available formulations of this compound were locally applied into tooth extraction sockets in animals, obtaining a significant delay in bone repair with respect to control sites, as histomorphometrically assessed (7) .
The diffusion ofASA-based long-term therapies in the whole population, e.g. the primary and secondary prevention of cardiovascular diseases, as well as the frequent post-surgical prescription of NSAIDs to reduce pain and inflammation, force to reflect on the possible side effects of these drugs on the success of all those therapies in which bone healing represents a key process, including orthopaedic, as well as oral and maxillo-facial procedures. In fact, the proper engrafting of autologous bone or bone substitutes into a receiving site, as well as the osseointegration of titanium implants (i.e. the new formation of mineralized tissue in close contact to the implant surface) could be affected by a concomitant use of ASA or other NSAIDs, and the clinical significance of these side effects could be of great impact.
Bone healing is a complex process involving a wide spectrum of cells and biological mediators. Bone marrow stromal cells (BMSCs) play a crucial role in these events, giving rise to the osteoprogenitors, and participating in the normal turnover, remodelling and repair of bone.
Recent in vitro studies have demonstrated the inhibitory effects of NSAIDs on bone cells, such as animal-(8-9) or human-derived osteoblasts (10) . Concerning ASA, it has been shown that this molecule inhibits the growth of a number of cell types (11) (12) (13) (14) , but very few data on its effects on BMSCs proliferation (15) , as well as on their differentiation, are available so far.
In the present study we investigated the biological response of primary human BMSCs to therapeutic doses of ASA in terms of cell proliferation and matrix mineralization.
MATERIALS AND METHODS
Tissue culture biochemicals were purchased from Gibco BRL (Grand Island, NY, USA), and plasticware from BD Falcon (Franklin Lakes, NJ, USA).
[3H]_ thymidine was purchased from Amersham Life Science (Buckinghamshire, UK). ASA and all other chemicals were obtained from Sigma (St. Louis, MO, USA).
Preparation and characterization ofhuman bone marrow stromal cells
Ten ml samples ofhuman bone marrow were harvested from three healthy donors (1 woman and 2 men, aged 25-40 years). Informed consent was provided according to the Declaration of Helsinki. The research was institutionally approved. BMSCs cultures were initiated as previously described (16) . Briefly, heparinized bone marrow was diluted 1:5 with complete culture medium consisting of Opti-MEM containing 10% (vol/vol) fetal calf serum (FCS), 100 units/ml penicillin, 100 ug/rnl streptomycin and 50 ug/ml sodium ascorbate, and incubated at 37 DC in a 5% CO 2 humidified atmosphere. Although present in an extremely low percentage compared to the total of mononuclear cells originally present in the bone marrow, BMSCs can be obtained by a method based on their ability to adhere to the bottom of polystyrene plates, while the cells of the haemopoietic lineage, which do not have such a capacity, remain in suspension and can be easily removed. After 48 h, the medium containing all non-adherent cellular elements was centrifuged 10 min at 800 x g in order to remove the haematopoietic cells, and added again to the dish. In 3-4 days, several foci of adherent spindle-like cells appeared and reached the subconfluence in 2 weeks. The medium was refreshed every 3 days, each time leaving one half of the old medium. The cells harvested from each donor were kept separately and not pooled with other preparations. Cultures between the second and fourth passage were used in our experiments.
Preparation of ASA experimental solutions and cell treatment
ASA in powder was dissolved in ethanol in order to obtain a 100 mg/ml stock solution and further diluted in culture medium to obtain the experimental ASA concentration (50, 100 and 200 ug/ml). All solutions were prepared each time immediately before use. Control solutions were prepared, dissolving in the culture medium an amount of ethanol equivalent to that present in the experimental ASA solutions.
Cell viability evaluation (MIT test)
Cell viability was measured by MTT assay. The key component of MTT test is 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. Mitochondrial dehydrogenases ofliving cells reduce the tetrazolium ring, yielding a blue formazan product, which can be measured spectrophotometrically. The amount offormazan produced is proportional to the number of viable cells present.
In brief, cells were plated at low density (5x10 4 cells/ well) in l2-well plates. The following day, cell cultures were starved by a 24 h-incubation with low serum medium (Opti-MEM plus 1% FCS) and then treated with ASA dilutions. After a 96 h-incubation with experimental solutions, MTT assay was carried out. Briefly, MTT (5 mg/ml in DMEM without phenol red) was added to the wells in an amount equivalent to 10% of the culture medium. After an incubation of 4 h at 37°C, the liquid was aspirated and the insoluble formazan produced was dissolved in isopropanol-HCI 0.1 N. The optical densities were measured at 570 nm, having subtracted the background absorbance determined at 690 nm.
DNA synthesis (rH]-thymidine incorporation)
Cell proliferation was measured by radiolabeled thymidine incorporation. In brief, BMSCs were plated at low density (5xl0 4 cells/well) in l2-well plates with complete medium. The following day, cell cultures were starved by a 24 h-incubation with low serum medium (Opti-MEM plus 1% FCS) and then treated with aspirin dilutions. After a 72 h-incubation with ASA, BMSCs were pulse-labeled with [3H]-thymidine (1~Ci/mllwell). Cells were then washed twice with phosphate buffered saline and lysed with 2 ml/well of 1% SDS-NaOH 0.3 M. The incorporated thymidine was measured with a liquid scintillation counter (Wallac 1409 DSA, Perkin-Elmer, MA, USA).
Cell cycle analysis
Cell suspensions from cell cultures grown in absence or in presence ofASA 50, 100 and 200 ug/ml for 72 h were prepared by trypsinizing the cells and washing them twice with phosphate buffered saline. Cells were resuspended at a density of 10 6 cells/ml in a staining solution containing 3.8 mM sodium citrate, 50 ug/ml propidium iodide, 0.5 ug/ml RNase A for 30 min at room temperature. The DNA content was analysed using a FACScalibur Flow Cytometer (Becton Dickinson, San Jose, CA, USA) and cell cycle data were analysed with Multicycle Software Autofit Version 2.50 (Phoenix Flow Systems, San Diego, CA, USA).
The content of p27 Kipl, p16Ink4A, p2l Cipl was quantified by immunoblotting. Monoclonal antibodies against p27 Kipl were from Transduction Laboratories (Lexington, KY, USA). The polyclonal antibodies to p l6 Ink4A, p2l Cip1 and actin were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Cell extracts and immunoblotting analyses for cyclin-dependent kinase inhibitors were performed as described (17) .
Extracellular matrix mineralization
In order to induce extracellular matrix mineralization, control and treated BMSCs were cultured for 3 weeks in presence of osteogenic medium (culture medium supplemented with 10 mM p-glycerophosphate, 100 nM dexamethasone). At the end ofthis period, both von Kossa staining and calcium level determination were carried out. For von Kossa assay, the cells were fixed with 1% glutaraldehyde, incubated with freshly prepared 5% silver nitrate in the dark for 15 min, then washed with distilled water and exposed to the sunlight for 15 min. The calcium levels were measured using o-cresolphthalein complex one method. Briefly, cells were decalcified with 0.6 N HCI for 24 h and the calcium released in the supernatant was determined colorimetrically at 575 nm.
Statistical analysis
All the experiments were performed in triplicate on at least two different cell preparations. Data are expressed as the mean ± standard deviation (SD). The differences between treated and untreated cells were detected by the unpaired Student t-test. In all cases the significance level was set at the p < 0.05.
RESULTS

Effects ofASA on BMSCs proliferation
Therapeutic doses of aspirin with antipyretic, analgesic and anti-inflammatory action result in serum levels in the 100-300 ug/ml range (1). Therefore, in our experiments we used ASA amounts ranging from 50 to 200 ug/ml, As shown in Fig. 1 
. Microscopic appearance of human bone marrow stromal cell growth in the presence of increasing amounts of acetylsalicylic acid (ASA). Large empty spaces and reduced cell density are evident at the higher concentrations .
the control culture (data not shown), suggesting that the growth inhibition of BMSCs was not the result of apoptosis or necrosis. The molecule inhibited cell proliferation, measured by MTT assay, in a dose-dependent manner at 3 days (Fig . 2a) . A significant (p<O.O I) decrease of cell growth became evident with a dose of 100 ug/rnl, reaching the maximum effect at 200 ug/rnl. Similar results were obtained by measuring the radio-labeled thymidine incorporated in the DNA. DNA synthesis decreased, in a dose-dependent manner, when BMSCs were exposed for 3 days to serial concentrations of ASA. In this case, the antiproliferative effect appeared even more evident, with a maximum decrease in 3H-thymidine incorporation of about 60% of control in BMSCs incubated with ASA 200 ug/rnl (p<O.O I, Fig. 2b) .
Cell cycle analysis highlighted a decrease of cells in the Sand G2/M phases, with a concomitant increase in GOII ofthe ASA-treated cells (Fig. 2c) On the basis of these findings, we studied the effect of ASA on the levels of some CDKIs, which play a pivotal role in controlling the transition of cells from the G I to S phase. Moreover, several studies have demonstrated that the CDKls are involved in the anti-proliferative activity of a number of drugs. As reported in Ft 3, ASA was able to up-regulate the level of p27 ip I at all the concentrations employed. The effect of the molecule was also evident on p2 ICip I, although this effect occurred only at 200 ug/rnl ASA concentration. Finally, the aspirin did not affect p 16Ink4A level at any of the amounts employed.
Effects of ASA on extracellular matrix mineralization
Serial concentrations ofASA (50, 100 and 200 Ilg/ ml) affected the extracellular matrix mineralization, which constitutes the final step of the phenotypic commitment of BMSCs to osteoblasts. Indeed, the calcium content was strongly reduced in ASAtreated cells with respect to control after 21 days of incubation, in a dose-dependent manner (Fig. 4a) . Accordingly, von Kossa staining directly confirmed the decrease of matrix calcification (Fig. 4b) .
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DISCUSSION c
The inhibitory effect of NSAIDs on the bone healing process has raised concerns due to the possible side effects when prescribed after bone fracture or in cases of bone surgery. Osteoprogenitors, which are involved in bone repair and regeneration, take origin from BMSCs, the mesenchymal component of the bone marrow.
Our results demonstrate that ASA, at doses within the therapeutic range, inhibited BMSCs proliferation and matrix mineralization.
ASA showed to reduce BMSCs growth and DNA synthesis in a dose-dependent manner. The present results are in agreement with other studies demonstrating that aspirin, at the same concentrations used in our study, is able to inhibit the proliferation ofa variety ofcells including osteoblasts, endothelial cells, and cancer cells (11) (12) (13) (14) .
The observed cell growth inhibition was assessed by a decrease in both cell viability (MTT test) and DNA synthesis CH-thymidine incorporation). Furthermore, trypan blue dye exclusion experiments ruled out any difference in the number of dead cells in ASA-treated samples compared to control.
Taken together, these data suggest that the dosedependent reduction of viability in ASA-treated cells was due to the inhibition of cell proliferation, rather than to cell death. Furthermore, the analysis of cell distribution in the various phases of cell cycle suggested, at least in part, that ASA induces the accumulation of cells in GO/I with a concomitant decrease of cells in Sand G2/M. The antiproliferative effect of ASA was further confirmed by the evaluation of its effect on the level of cyclindependent kinase inhibitors. Indeed , ASA has shown to induce a significant increase of both p27Kip I and p21Cip I, confirming that the effect of the molecule results in an accumulation of cells in the G I phase.
Regardless of the mechanism, the observed inhibitory effect on BMSC growth could have some important clinical implications. Indeed, these cells are directly involved in the bone healing process , and ASA could hamper the formation of the necessary critical mass of cells required for synthesizing the reparative bone matrix , resulting in a delayed healing process.
In addition to these effects on the cell growth machinery, ASA showed also to affect BMSC osteogenic function. The differentiation of these cells toward the osteoblastic phenotype is a complex process which follows a precise temporal sequence involving several phases . The mineralization of the extracellular matr ix, namely the precipitation of hydroxyapatite crystals upon the extracellular collagenic network, repre sents the final step of the differentiative process. Our results show that the extracellular matri x mineralization was clearly inhibited by ASA in a dose -dependent fashion. Thus , on the basis of our findings, we can hypothesize a mult iple inhibitory mechanism of ASA on bone metabolism : either by the reduct ion of BMSC proliferation, via the block of cell cycle machinery, or by the alteration of osteogenic functions, through the impairment of matri x mineralization.
Few data are available on the action of ASA on bone cells. The effects observed in our study could be explained by the cyclooxygenases (COX )-mediated reduction of prostaglandin (PG) synthesis (18) (19) . Two COX isoforms participate in the PG synthesis. Particularly, COX-I is a constitutive form while COX-II is inducible. While the ASA effects on COX-I is mostly related to its negati ve sideeffects , the therapeutic activitie s of the molecule seem to be due to the inhibition of COX-II (18) (19) . This latter enzyme has been shown to be critically involved in bone repair, being up-regulated during the initial stages of this process (20) and regulating the osteogenic differentiation of BMSCs (21) ; for this reason, its inhibition could lead to detrimental effects on these processes. In this perspective, the observed effects of ASA on BMSC response could be mainly due to its action on COX-II and PG synthesis by an autocrine/paracrine mechanism of action. In fact, PGs play a crucial role in the bone healing process (22) . In particular, PGE2 has been shown to induce bone nodules in rat bone marrow stromal cell cultures (23) and calvaria osteoblasts (24) (25) . Furthermore, a direct link between PGE2 levels and BMSC differentiation has been pointed out, through the induction of cbfal and osterix, two genes necessary for BMSC differentiation and for a normal osteogenesis (26) . In a wider and more physiologic context, several other aspects must be taken into account that influence the extrapolation of our findings to the in vivo situation. For instance, the role of the inflammatory cytokines IL-l and TNF-alpha on the inhibition of bone matrix synthesis, not mediated by prostaglandins and not affected by NSAIDs, cannot be ruled out (27) .
In conclusion, our results support the view that the largely reported inhibition of bone healing by ASA might be sustained by a direct anti-proliferative effect on BMSCs at therapeutic doses. In addition, ASA showed to affect the osteogenic functions through the impairment of matrix mineralization. Further studies are needed to define the precise molecular mechanisms of such effects, and to clarify their significance in clinical practice.
